Form 4: OCUL Executive Shifts 250K Shares to Trust

Ocular Therapeutix's Executive Chairman, Pravin Dugel, transferred 250,361 shares to a trust, retaining beneficial ownership.

Summary

• Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, Inc. (OCUL), engaged in a series of non-consideration stock transfers.
• On April 28, 2025, he transferred 200,332 shares of common stock to his spouse for no consideration, reducing his direct beneficial ownership to 3,298,767 shares.
• On June 12, 2025, he transferred an additional 50,029 shares of common stock to his spouse for no consideration, further reducing his direct beneficial ownership to 3,248,738 shares.
• On August 11, 2025, his spouse transferred a total of 250,361 shares (the sum of the two previous transfers) to the Pravin Dugel 2024 Irrevocable Trust.
• Pravin Dugel is the trustee and sole lifetime beneficiary of this Trust, meaning he retains beneficial ownership of these 250,361 shares, now held indirectly.
• His total beneficial ownership remains 3,499,099 shares (3,248,738 direct + 250,361 indirect).

Sentiment

Score: 6

Explanation: The filing details internal transfers of shares for estate planning purposes by a key executive, with beneficial ownership retained. This is a neutral event for the company's operations but can be seen as slightly positive as it indicates the executive's long-term commitment and structured approach to his holdings, without divesting.

Positives

• The transfers to an irrevocable trust, where the reporting person remains the sole lifetime beneficiary, indicate a structured approach to wealth management and estate planning.
• Retention of beneficial ownership by the Executive Chairman, President, and CEO signals continued alignment of his interests with shareholders.

Management Comments

• Executive Chairman, President and CEO (Pravin Dugel's roles).
• The reporting person is trustee of the Trust and sole beneficiary of the Trust during his lifetime. The reporting person remains the beneficial owner of the securities held by the Trust.

Related Party Transactions

• Transfer of 200,332 shares to spouse for no consideration on April 28, 2025.
• Transfer of 50,029 shares to spouse for no consideration on June 12, 2025.
• Transfer of 250,361 shares from spouse to Pravin Dugel 2024 Irrevocable Trust for no consideration on August 11, 2025, where Pravin Dugel is trustee and sole lifetime beneficiary.

Stakeholder Impact

• Shareholders: No direct impact on company operations or share count. The executive's continued beneficial ownership aligns his interests with shareholders.
• Employees, Customers, Suppliers, Creditors: No direct impact.

Key Dates

Recommendation

This Form 4 filing details an executive's internal share transfers for estate planning, where beneficial ownership is retained. It does not provide new information regarding the company's financial performance, strategic direction, or operational health. Therefore, it offers no basis for a change in investment recommendation; existing investment theses should remain unchanged.

Keywords

Ocular Therapeutix, OCUL, Pravin Dugel, SEC Form 4, insider transaction, stock transfer, beneficial ownership, trust, estate planning, common stock